Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Liver Cancer Specialty Channel

Liver Cancer
Specialty Channel
News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
Adding Durvalumab, Bevacizumab to TACE Improved Progression-Free Survival Among Patients With Unresectable Hepatocellular Carcinoma
01/19/2024
Allison Casey
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the...
01/19/2024
Oncology
News
Antiviral Therapy Found to Improve Long-Term Survival for Patients With HBV- and HCV-Related Hepatocellular Carcinoma
01/12/2024
Allison Casey
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective...
01/12/2024
Oncology
News
Proton Beam Radiotherapy as Treatment Alternative to TACE for Patients With Hepatocellular Carcinoma
08/10/2023

Allison Casey 

Allison Casey 
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial,...
08/10/2023
Oncology
News
Clinicopathological Differences Between Resected Hepatocellular Carcinoma Caused by NAFLD/NASH and Other Etiologies
03/24/2023

Allison Casey

Allison Casey
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis,...
03/24/2023
Oncology
Conference Coverage
Tislelizumab Yields Better Health-Related Quality of Life Outcomes vs Sorafenib for Patients With Unresectable Hepatocellular Carcinoma
01/20/2023
Allison Casey
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular...
01/20/2023
Oncology
News
FDA Approves Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma
10/26/2022
Allison Casey
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to...
10/26/2022
Oncology
Quiz
Quiz: Which options was found to be a potential first-line treatment for hepatocellular carcinoma?
10/17/2022
Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.
Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.
Do you know which option was...
10/17/2022
Oncology
News
Ramucirumab Safe and Effective for Patients With Hepatocellular Carcinoma With No Prior Sorafenib Treatment
10/07/2022

Allison Casey

Allison Casey
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort...
10/07/2022
Oncology
News
Transarterial Chemoembolization Added to Lenvatinib Improves Clinical Outcomes in Hepatocellular Carcinoma
09/08/2022

Allison Casey

Allison Casey
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial...
09/08/2022
Oncology

Advertisement

News

News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
Adding Durvalumab, Bevacizumab to TACE Improved Progression-Free Survival Among Patients With Unresectable Hepatocellular Carcinoma
01/19/2024
Allison Casey
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the...
01/19/2024
Oncology
News
Antiviral Therapy Found to Improve Long-Term Survival for Patients With HBV- and HCV-Related Hepatocellular Carcinoma
01/12/2024
Allison Casey
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective...
01/12/2024
Oncology
News
Proton Beam Radiotherapy as Treatment Alternative to TACE for Patients With Hepatocellular Carcinoma
08/10/2023

Allison Casey 

Allison Casey 
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial,...
08/10/2023
Oncology
News
Clinicopathological Differences Between Resected Hepatocellular Carcinoma Caused by NAFLD/NASH and Other Etiologies
03/24/2023

Allison Casey

Allison Casey
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis,...
03/24/2023
Oncology
Conference Coverage
Tislelizumab Yields Better Health-Related Quality of Life Outcomes vs Sorafenib for Patients With Unresectable Hepatocellular Carcinoma
01/20/2023
Allison Casey
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular...
01/20/2023
Oncology
News
FDA Approves Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma
10/26/2022
Allison Casey
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to...
10/26/2022
Oncology
News
Ramucirumab Safe and Effective for Patients With Hepatocellular Carcinoma With No Prior Sorafenib Treatment
10/07/2022

Allison Casey

Allison Casey
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort...
10/07/2022
Oncology
News
Transarterial Chemoembolization Added to Lenvatinib Improves Clinical Outcomes in Hepatocellular Carcinoma
09/08/2022

Allison Casey

Allison Casey
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial...
09/08/2022
Oncology

Interactive Features

Quiz
Quiz: Which options was found to be a potential first-line treatment for hepatocellular carcinoma?
10/17/2022
Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.
Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.
Do you know which option was...
10/17/2022
Oncology
Quiz
Quiz: Cabozantinib Plus Atezolizumab for Advanced Hepatocellular Carcinoma
09/02/2022
Did cabozantinib plus atezolizumab significantly improve clinically meaningful end points for patients with advanced hepatocellular carcinoma who had not previously received systemic cancer therapy when compared to sorafenib?
Did cabozantinib plus atezolizumab significantly improve clinically meaningful end points for patients with advanced hepatocellular carcinoma who had not previously received systemic cancer therapy when compared to sorafenib?
Did cabozantinib plus...
09/02/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
News
Antiviral Therapy Found to Improve Long-Term Survival for Patients With HBV- and HCV-Related Hepatocellular Carcinoma
01/12/2024
Allison Casey
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective...
01/12/2024
Oncology
News
Proton Beam Radiotherapy as Treatment Alternative to TACE for Patients With Hepatocellular Carcinoma
08/10/2023

Allison Casey 

Allison Casey 
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial,...
08/10/2023
Oncology
News
Clinicopathological Differences Between Resected Hepatocellular Carcinoma Caused by NAFLD/NASH and Other Etiologies
03/24/2023

Allison Casey

Allison Casey
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis,...
03/24/2023
Oncology
News
FDA Approves Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma
10/26/2022
Allison Casey
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to...
10/26/2022
Oncology
News
Ramucirumab Safe and Effective for Patients With Hepatocellular Carcinoma With No Prior Sorafenib Treatment
10/07/2022

Allison Casey

Allison Casey
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort...
10/07/2022
Oncology
News
Transarterial Chemoembolization Added to Lenvatinib Improves Clinical Outcomes in Hepatocellular Carcinoma
09/08/2022

Allison Casey

Allison Casey
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial...
09/08/2022
Oncology
News
Cabozantinib Plus Atezolizumab vs Sorafenib for Advanced Hepatocellular Carcinoma: COSMIC-312 Trial
08/19/2022

Allison Casey

Allison Casey
Cabozantinib plus atezolizumab significantly prolongs PFS vs sorafenib for patients with advanced hepatocellular carcinoma not amenable to curative treatment or locoregional therapy, according to results from the phase 3 COSMIC-312 study.
Cabozantinib plus atezolizumab significantly prolongs PFS vs sorafenib for patients with advanced hepatocellular carcinoma not amenable to curative treatment or locoregional therapy, according to results from the phase 3 COSMIC-312 study.
Cabozantinib plus atezolizumab...
08/19/2022
Oncology
Conference Insider
Equivalent Clinical Outcomes With Sorafenib in Younger and Older Patients With Advanced HCC
06/29/2021
According to data presented at the virtual ESMO World Congress on GI Cancer, low-dose sorafenib yields equivalent clinical outcomes in younger and older-aged patients with advanced HCC.
According to data presented at the virtual ESMO World Congress on GI Cancer, low-dose sorafenib yields equivalent clinical outcomes in younger and older-aged patients with advanced HCC.
According to data presented at...
06/29/2021
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement